UK Markets open in 6 hrs 19 mins

Merck & Co., Inc. (6MK.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
53.965-0.035 (-0.065%)
At close: 7:50PM CEST
Full screen
Previous close54.000
Bid53.896 x 100000
Ask53.964 x 100000
Day's range53.561 - 54.067
52-week range50.988 - 63.309
Avg. volume1,091
Market cap154.47B
PE ratio (TTM)34.39
EPS (TTM)1.57
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Reuters3 hours ago

    Merck immunotherapy fails to improve survival in head and neck cancer

    Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than the standard combination therapy in a late-stage trial. The drug, which blocks a mechanism tumors use to hide from the immune system allowing it to recognize and attack the cancer, won accelerated U.S. approval last August for these patients based on its ability to shrink tumors. As a condition of the accelerated approval, Merck was required to conduct a trial to demonstrate superiority over standard treatment and verify the clinical benefit of Keytruda in this patient population.

  • Benzinga5 hours ago

    Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers

    Pharmaceutical giants Bristol-Myers Squibb Co (NYSE: BMY ) and Merck & Co., Inc. (NYSE: MRK ) both release their second quarter earnings reports this week. According to BMO Capital, investors should be ...

  • Merck, Samsung Accelerate a Biosimilar Price War
    Bloomberg6 hours ago

    Merck, Samsung Accelerate a Biosimilar Price War

    The days of high-priced knockoffs of biologic drugs are ending quickly.